LifeSci Capital Sticks to Their Buy Rating for Liquidia Technologies (LQDA)
TipRanks (Sat, 25-Jul 10:45 AM ET)
CLO, Kingsoft, Liquidia, Marsh, Victoria’s Secret Sell-Offs
TipRanks (Sat, 25-Jul 9:01 AM ET)
Major Insider Move at Liquidia Technologies Shakes Up Investor Outlook
TipRanks (Fri, 24-Jul 10:01 PM ET)
TipRanks (Thu, 23-Jul 1:10 PM ET)
Major Insider Move Shakes Up Liquidia Technologies
TipRanks (Wed, 22-Jul 10:01 PM ET)
TipRanks (Wed, 22-Jul 4:05 PM ET)
Liquidia jumps as judge criticizes United Therapeutics in patent dispute
Seeking Alpha News (Wed, 22-Jul 12:51 PM ET)
Liquidia Highlights Patient-Focused Research and Caregiver Insights at 2026 PH Conference
Market Chameleon (Fri, 12-Jun 7:43 AM ET)
Market Chameleon (Thu, 11-Jun 4:44 AM ET)
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of July 27, 2026, LQDA stock price declined to $84.42 with 1,375,357 million shares trading.
LQDA has a beta of 1.05, meaning it tends to be more sensitive to market movements. LQDA has a correlation of 0.04 to the broad based SPY ETF.
LQDA has a market cap of $7.50 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $133 million in Revenue and $.52 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.13.
In the last 3 years, LQDA traded as high as $91.10 and as low as $5.71.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
LQDA has outperformed the market in the last year with a price return of +349.8% while the SPY ETF gained +17.7%. LQDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +126.3% and +8.3%, respectively, while the SPY returned +3.8% and -2.1%, respectively.
LQDA support price is $82.25 and resistance is $90.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.